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ABsTrACT
Eosinophils are key effector cells in allergic diseases. 
Here we investigated Mcl-1 (an anti- apoptotic protein) 
in experimental allergic airway inflammation using 
transgenic overexpressing human Mcl-1 mice (hMcl-
1) and reducing Mcl-1 by a cyclin- dependent kinase 
inhibitor. Overexpression of Mcl-1 exacerbated allergic 
airway inflammation, with increased bronchoalveolar 
lavage fluid cellularity, eosinophil numbers and total 
protein, and an increase in airway mucus production. 
Eosinophil apoptosis was suppressed by Mcl-1 
overexpression, with this resistance to apoptosis 
attenuated by cyclin- dependent kinase inhibition 
which also rescued Mcl-1- exacerbated allergic airway 
inflammation. We propose that targeting Mcl-1 may be 
beneficial in treatment of allergic airway disease.
InTroduCTIon
Eosinophils are key immune cells in the pathogen-
esis and propagation of allergic airway diseases, 
including eosinophilic asthma.1–3 The restora-
tion of tissue homoeostasis following inflamma-
tion requires the cessation of proinflammatory 
signalling and removal of recruited immune cells.4 
Resolution of eosinophilic inflammation can be 
achieved through a combination of inflammatory 
cell apoptosis and subsequent phagocytic removal 
(efferocytosis), via transepithelial migration and 
mucociliary clearance, or via alternative forms of 
death including necrosis.5 Notably, reduced eosino-
phil apoptosis and defective efferocytosis are both 
reported in asthmatic patients, and are associated 
with increasing disease severity. These observations 
suggest the importance of these mechanisms in the 
resolution of allergic disease.
We have shown that downregulation of Mcl-1 in 
human eosinophils occurs concurrent with induc-
tion of apoptosis following treatment with cyclin- 
dependent kinase inhibitor (CDKi) drugs, and that 
induction of eosinophil apoptosis attenuates allergic 
lung inflammation in mice in vivo.6 In addition, 
eosinophil Mcl-1 can be dynamically regulated in 
response to proinflammatory cytokines. Together, 
these findings suggest that Mcl-1 may be a poten-
tial target for ameliorating allergic disease. Despite 
this, the direct effects of Mcl-1 on allergic airway 
inflammation in vivo have not been determined. 
Here we investigated the impact of manipulating 
Mcl-1, using both pharmacological and genetic 
approaches, on eosinophil viability and allergic 
airway inflammation.
MeThods
In vivo experiments were performed under the UK 
Home Office Animals (Scientific Procedures) Act 
1986, following approval by local ethics committee. 
Female mice (8 to 16 week; wild type (WT) 
(Charles River or littermate controls)) and trans-
genic mice overexpressing human Mcl-1 (hMcl-1)7 
on a C57Bl6 background underwent ovalbumin 
(OVA)- induced allergic airway inflammation, with 
bronchoalveolar lavage fluid (BALF) and tissue 
acquired and processed as described.1 6 AT7519 
(30 mg/kg in sterile saline) was administered as 
a single intraperitoneal dose. Mice were housed 
in a specific- pathogen- free facility with standard 
husbandry. Mice were not randomised but allo-
cated on the basis of genotype, with a single animal 
serving as the experimental unit, with all treatments 
and assessments performed in the morning. BALF 
total cell counts were measured by NucleoCounter 
with BALF cell composition analysed by flow 
cytometry. Interstitial cells were analysed following 
collagenase digest of lungs after bronchoalveolar 
lavage and perfusion with phosphate- buffered 
saline. Lung histology was blinded prior to anal-
ysis by a lung pathologist. Cytokines were analysed 
by ELISA (BALF) or Luminex (lung homogenate). 
For ex vivo culture of BALF eosinophils (CD45+ve/
CD11c- ve/Ly6G- ve/Siglec- F+ve), BALF cells were 
incubated (5×106/mL) in serum- free Iscove’s Modi-
fied Dulbecco’s Medium (IMDM) for 48 hours 
+/-AT7519, Q- VD- OPh as per figure legends.
Mouse bone marrow- derived eosinophils 
(bmEos) were generated from WT and hMcl-1 
mice as described.1 Light microscopy or flow cyto-
metric analysis of Annexin- V/propidium iodide (PI) 
or DAPI staining was used to identify viable, apop-
totic and necrotic bmEos. Western blotting was 
performed as described.1 8 9
Data expressed as mean±SEM, analysed using 
GraphPad Prism and FlowJo software. Significance 
accepted at p<0.05.
resulTs
Mcl-1 overexpression exacerbates allergic airway 
inflammation in vivo
To investigate Mcl-1 in allergic airway inflamma-
tion, WT or hMcl-1 mice were sensitised and chal-
lenged with OVA (or PBS as control)6 (figure 1A). 
Western blotting confirmed expression of human 
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Figure 1 Overexpression of Mcl-1 exacerbates allergic airway inflammation in vivo. (A) Schema of experimental protocol, (B) total bronchoalveolar 
lavage fluid (BALF) cell counts assessed by NucleoCounter and (C) BALF eosinophil number analysed by flow cytometry (CD45+/CD11c-/Siglec- F+ 
Singlets) from PBS or OVA- challenged mice at day 26 (n=3 for PBS treated groups, n=8–10 for OVA groups). (D) Representative lung sections stained 
with periodic acid- Schiff (PAS) from WT and hMcl-1 mice (x200 original magnification, scale bar=150 µm) with (E) quantification of mucus production 
as assessed by the mucus- goblet index (MGI) (n=6 both groups). (F) BALF total protein (n=8 WT, n=10 hMcl-1), (G) lung interstitial eosinophils (as % 
of CD45+ events; n=7 WT, n=6 hMcl-1), (H) BALF IL-5 & eotaxin-1 cytokine levels (eotaxin n=8 WT, n=9 hMcl-1, IL-5; n=4 WT, n=7 (hMcl-1), and (I) 
lung cytokines (n=7 WT, n=6 hMcl-1). The percentage of (J) viable (annexin V- ve/PI- ve cells) and (K) apoptotic (annexin V+ve/PI- ve) BALF eosinophils (n=8 
WT, n=8 hMcl-1), assessed by flow cytometry. Data analysed by one- way analysis of variance with a Newman- Keuls multiple- comparisons test (B and 
C), or by Student’s t- test (E–I). hMcl-1,human Mcl-1; ip, intraperitoneal; ns=non significant; OVA, ovalbumin; PBS, phosphate- buffered saline; WT, wild 
type.
Mcl-1 in bmEos) from hMcl-1 mice (online supplementary figure 
1). No change in BALF total cell counts or eosinophil numbers 
(online supplementary figure 2) were observed in hMcl-1 trans-
genic mice following PBS challenge (figure 1B,C). However, 
hMcl-1 mice had an exacerbated allergic response to OVA 
with increased BALF cellularity, eosinophil numbers, airway 
mucus production and BALF total protein (figure 1B–F), with 
an increase in the proportion of interstitial eosinophils that did 
not reach statistical significance (figure 1G). The proportion of 
lung alveolar macrophages, neutrophils and T cell subsets were 
similar between WT and hMcl-1 mice following OVA (online 
supplementary figure 3). Despite increased eosinophils in hMcl-1 
mice, BALF eotaxin (CCL11) and IL-5 (key cytokines for eosin-
ophil recruitment and lifespan) were unaltered (figure 1H), with 
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Figure 2 Overexpression of Mcl-1 delays bone marrow- derived eosinophil (bmEos) and airway eosinophil apoptosis. (A and B) WT and hMcl-1 
transgenic bmEos were cultured over 48 hours with assessment of eosinophil viability and apoptosis by flow cytometry (annexin V/propidium iodide 
binding) (n=5 WT, n=4 hMcl-1). (B) Representative cytocentrifuge preparations (×1000 original magnification, scale bar=20 µm) at 16 and 24 hours 
for WT and hMcl-1 bmEos. Black arrows point to bmEos with apoptotic morphology, Grey arrowheads indicate cellular fragmentation of bmEos. 
(C and D) Airway eosinophils from WT and hMcl-1 OVA- challenged mice were cultured over 48 hours prior to assessment of (C) viability and (D) 
apoptosis by flow cytometry (annexin V/DAPI binding) (n=8 WT, n=8 hMcl-1 at 0 hour; n=4 WT, n=5 hMcl-1 at 6 hour, 24 hours & 48 hours). Data are 
expressed as mean±SEM as analysed by two- way analysis of variance with a Bonferroni test, p values as indicated. BALF, bronchoalveolar lavage 
fluid; hMcl-1, human Mcl-1; OVA,ovalbumin; WT, wild type.
multiple cytokines from homogenised lung showing similar levels 
between WT and hMcl-1 mice (although with a trend towards 
increased IL-4 in the hMcl-1 mice; 18.2±2.9 vs 28.4±4.0 pg/mL 
p=0.06, figure 1I) . However, the proportion of viable eosin-
ophils (Annexin V- ve/PI- ve) was increased in hMcl-1 mice, with 
a concurrent reduction in apoptotic eosinophils (Annexin V+ve/
PI- ve; figure 1J,K).
Mcl-1 overexpression delays eosinophil death
We next investigated whether enhanced eosinophil viability in the 
hMcl-1 mice in vivo was intrinsic to eosinophils or a secondary 
phenomenon due to potential alterations in the inflammatory 
milieu. Serum and IL-5- starvation of bmEos demonstrated 
that hMcl-1 bmEos had enhanced viability (figure 2A,B). Simi-
larly, airway eosinophils from OVA- challenged hMcl-1 mice 
demonstrated enhanced survival (figure 2C) and reduced apop-
tosis (figure 2D) during ex vivo culture.
The cyclin-dependent kinase inhibitor AT7519 reverses 
delayed eosinophil apoptosis in hMcl-1 mice to rescue 
allergic inflammation
The CDKi AT7519 increased apoptosis of airway eosinophils 
from hMcl-1 mice. This AT7519- induced apoptosis was caspase- 
dependent (inhibited by the broad- spectrum caspase inhib-
itor Q- VD) and was associated with reduced Mcl-1 expression 
(figure 3A–C). To assess the therapeutic potential of AT7519 
to attenuate Mcl-1- exacerbated allergic airway inflammation 
in vivo, AT7519 was administered 24 hours after intratra-
cheal ovalbumin (figure 4A). This significantly reduced BALF 
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Figure 3 AT7519 reverses delayed eosinophil apoptosis. (A) Eosinophil apoptosis (AnnV+ve/Ly6G−ve/Siglec- F+ve) from WT and hMcl-1 mice at 
24 hours with AT7519 (1 µM) with or without the caspase inhibitor Q- VD (10 µM) as assessed by flow cytometry (n=3–4). (B) Bronchoalveolar lavage 
cells from WT or hMcl-1 OVA- challenged mice treated +/-AT7519 (1 µM) for 4 hours prior to lysing and Western blotting for hMcl-1 (40KD), mouse 
Mcl-1 (35kD) and β-actin (42kD). (C) Representative cytocentrifuge preparations (×1000 original magnification, scale bar=20 µm) at 6 hours for 
WT and hMcl-1 control cells and hMcl-1 cells treated with AT7519 (1 µM) and combined AT7519 (1 µM) and Q- VD (10 µM). Black arrows indicate 
apoptotic eosinophils. Data expressed as mean±SEM, analysed by one- way analysis of variance with a Newman- Keuls multiple- comparisons test, 
###p< 0.001 versus AT7519- treated group or as indicated (A). hMcl-1,human Mcl-1; OVA, ovalbumin; WT, wild type.
cellularity and eosinophils, with increased Annexin V+ve eosin-
ophils (figure 4B–D). H&E sections demonstrated a reduction 
in the number of perivascular and peribronchial eosinophils and 
lymphocytes following treatment with AT7519 (figure 4E–G) 
while no difference was observed in bronchial mucin produc-
tion by PAS staining (data not shown). Analysis of lung cytokines 
demonstrated a reduction in IL-4 and increases in IL-5 and IL-6 
(figure 4H). Overall, these data confirmed that AT7519 rescues 
Mcl-1- exacerbated allergic airway inflammation in vivo.
dIsCussIon
Understanding mechanisms and regulatory processes controlling 
inflammation resolution is the focus of recent intense investi-
gation.4 10 Mechanisms can be tissue and scenario dependent, 
but apoptosis and subsequent efferocytosis of inflammatory cells 
are recognised as major processes ensuring inflammation resolu-
tion and tissue repair. Here we determined the role of Mcl-1 in 
both the regulation of eosinophil lifespan and in driving allergic 
airway inflammation.
We report several novel findings that extend our under-
standing of eosinophil apoptosis in controlling inflammation 
and tissue injury in airway allergy. First, we show that overex-
pression of Mcl-1 leads to exacerbated allergic airway inflamma-
tion as determined by several inflammation parameters including 
BALF cellularity, eosinophil numbers, BALF protein and airway 
mucus production. Whether manipulation of Mcl-1 also leads to 
changes in airway hyperresponsiveness or remodelling remains 
to be determined, but is a logical future extension of our current 
work.
Second, we show that Mcl-1 overexpression reduces eosin-
ophil death both in vitro and in vivo in the context of airway 
allergy, extending our previous observations that Mcl-1 is a key 
regulator of neutrophil apoptosis,9 11 and that CDKi induce 
eosinophil apoptosis concurrent with Mcl-1 loss.12 While 
cytokine- mediated changes or maintenance in eosinophil Mcl-1 
(by IFN-γ and IL-5) have previously been reported, this is to 
our knowledge the first report that Mcl-1 aggravates allergic 
airway inflammation in vivo. While we cannot exclude the possi-
bility that the regulatory role of Mcl-1 on inflammation in vivo 
involves other cell types, we have previously shown that modu-
lation of eosinophil apoptosis or apoptotic eosinophil clearance 
is sufficient to alter allergic airway inflammation.1 6
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Figure 4 AT7519 reverses delayed eosinophil apoptosis in hMcl-1 mice to rescue allergic inflammation in vivo. (A) Schema of experimental protocol. 
(B) Total bronchoalveolar lavage fluid (BALF) cell counts from OVA- challenged hMcl-1 mice after 26 days with either PBS or AT7519 treatment on 
day 25. (C) BALF eosinophil number and (D) percentage of BALF apoptotic eosinophils (AnnV+ve/DAPI- ve, CD45+ve/CD11c- ve/Ly6G- ve/Siglec- F+ve cells). 
(B- D n=4 hMcl-1, n=6 +AT7519). (E) Representative lung sections stained with H&E (X100 original magnification) with (F) quantification of total 
inflammation and (G) peribronchial/perivascular inflammation. (H) Lung cytokines analysed by Luminex. (F- H n=6 hMcl-1, n=6 +AT7519). Data 
expressed as mean±SEM, analysed by Student’s t- test. hMcl-1,human Mcl-1; OVA, ovalbumin; PBS, phosphate- buffered saline.
Finally, we show that the apoptosis protection conferred to 
eosinophils by Mcl-1 overexpression could be overcome by 
pharmacological lowering of Mcl-1 levels using indirect Mcl-1 
inhibition with a CDKi. Furthermore, Mcl-1- exacerbated 
allergic inflammation in vivo could be rescued by the same 
approach suggesting that Mcl-1 targeting approaches are capable 
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of overriding the complex pro- survival signals that exist in the 
inflamed lung. Of note, this is in contrast to glucocorticoid- 
induced eosinophil apoptosis which can be abrogated by the 
presence of cytokines such as IL-5.
In summary, our results demonstrate Mcl-1 as a significant 
regulator of eosinophil longevity and the outcome of allergic 
airway inflammation in vivo. We propose that manipulation of 
Mcl-1 could be exploited for the treatment of allergic diseases 
such as eosinophilic asthma in humans.
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